Clinical Trial Update: Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability evaluation of ETC-1002 in high-risk hyperlipidemia patients completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Diseases
• Hypercholesterolemia

Drugs mentioned

• ETC-1002 (bempedoic acid)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2020-04-20